Lineage Cell Therapeutics, Inc.
LCTX
$1.68
$0.074.35%
AMEX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 33.13% | 84.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.13% | 84.09% | |||
| Cost of Revenue | -94.15% | 5.50% | |||
| Gross Profit | 1,020.26% | 74.31% | |||
| SG&A Expenses | -8.09% | -6.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.09% | -3.77% | |||
| Operating Income | 23.36% | 24.06% | |||
| Income Before Tax | 2.02% | -632.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.02% | -632.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 71.00% | -2,600.00% | |||
| Net Income | 2.24% | -636.02% | |||
| EBIT | 23.36% | 24.06% | |||
| EBITDA | 24.34% | 24.79% | |||
| EPS Basic | 2.47% | -628.96% | |||
| Normalized Basic EPS | -89.74% | -276.32% | |||
| EPS Diluted | 2.47% | -628.96% | |||
| Normalized Diluted EPS | -89.74% | -276.32% | |||
| Average Basic Shares Outstanding | 0.22% | 1.02% | |||
| Average Diluted Shares Outstanding | 0.22% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||